Eli Lilly LLY shares are trading higher on Monday after the company initiated a Phase 3 trial of LY-CoV555 for the prevention of COVID-19 at long-term care facilities in partnership with the NIAID.
Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.
Eli Lilly shares were trading up 1.30% to $152.24 at time of publication on Monday. The stock has a 52-week high of $170.75 and a 52-week low of $101.36.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
